Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Clinical trial NCT03463460 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03463460
- Sponsor
- Dwight Owen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-19
- Primary completion
- 2026-07-17
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.